CVS Health Corporation: enforcement record and regulatory exposure
CVS Health Corporation scores 87 out of 100 on the RedFlag Index™ (November 2026), ranking #1 of ten tracked companies, with 9 documented cases of which 5 remain open.
Documented record
December 2025: CVS paid $37.76 million under the False Claims Act for over-dispensing insulin pens, and admitted certain conduct.
2025: Omnicare, a CVS Health subsidiary, was hit with a $948.8 million judgment after a jury found more than 3.3 million false claims from 2010 to 2018.
December 2024: The DOJ sued CVS, alleging unlawful opioid dispensing since October 2013. The case is pending.
2022–2023: CVS agreed to pay about $5 billion over 10 years in the national opioid settlement.
2022: CVS paid Florida $484 million in a separate opioid settlement.
2020: Omnicare, a CVS Health subsidiary, paid $15.3 million for Controlled Substances Act violations.
Enforcement ledger
| Date | Matter | Amount | Status |
|---|---|---|---|
| October 30, 2026 | Oklahoma Caremark settlement over pharmacy transaction fees | $2.1m | Resolved |
| October 13, 2026 | DOJ Controlled Substances Act and FCA dispensing case, settled with DEA compliance agreement | $315m | Resolved, order in force |
| October 9, 2026 | Pennsylvania AG insulin pricing suit | Open | |
| July 14, 2026 | FTC insulin rebating consent order (Caremark, Zinc) | No penalty | Resolved, order in force |
| January 15, 2026 | Missouri AG insulin pricing suit | Open | |
| January 7, 2026 | Oregon AG insulin pricing suit ($900m sought) | Open | |
| December 2025 | Insulin-pen over-dispensing FCA settlement with admissions and CIA | $37.8m | Resolved, order in force |
| August 2025 | Caremark Medicare Part D FCA judgment (Behnke), on appeal | $289.9m | On appeal |
| July 2025 | Omnicare FCA jury verdict and judgment; Chapter 11 filing; $440m resolution proposed | $948.8m | Judgment |
| October 2024 | Texas AG insulin pricing suit | Open | |
| September 2024 | Oak Street Health FCA kickback settlement | $60m | Resolved |
| December 2022 | National opioid settlement (about $5bn over ten years) | $5bn | Resolved, order in force |
| 2022 | Florida opioid settlement | $484m | Resolved |
| 2020 | Omnicare Controlled Substances Act settlement | $15.3m | Resolved |
Government enforcement only. Greyed rows are more than ten years old and excluded from scoring under the temporal decay rule.
RegulationWatch coverage
- State Enforcement
Oklahoma to pay out $2.1 million from third CVS Caremark settlement over pharmacy fees
Oklahoma will distribute more than $2.1 million in fines from a settlement with CVS Caremark over transaction fees it allegedly charged pharmacies in violation of state law. It is the state's third Caremark settlement, taking the total returned to pharmacies above $7 million.
- PBM Oversight
House Oversight chair investigates whether PBMs used audits to punish pharmacies that backed reform
Chairman James Comer asked CVS Caremark, Express Scripts and Optum Rx for documents and briefings after independent pharmacies that supported H.R. 6610 reported a surge of burdensome audits. The companies have not been accused in any proceeding.
- Drug Pricing
Pennsylvania sues the three largest insulin makers and PBMs over alleged pricing scheme
Pennsylvania Attorney General Dave Sunday sued Eli Lilly, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark and OptumRx under the state's consumer protection law. Because Pennsylvania has no general antitrust statute, the case relies on deception claims rather than price-fixing law.
- Controlled Substances Act
CVS agrees to pay $315 million to settle federal opioid dispensing case
The Justice Department announced that CVS Pharmacy will pay $315 million to resolve Controlled Substances Act and False Claims Act allegations that it filled unlawful opioid prescriptions and billed federal programs for them. CVS admitted no liability and signed a compliance agreement with the DEA.
- PBM Rebates
Express Scripts settled the insulin case without paying a cent or admitting a thing.
The FTC's order changes how Cigna's pharmacy benefit manager behaves from here. It returns nothing for the years the agency says list prices were inflated.
- False Claims Act
A jury found 3.3 million false claims at CVS's Omnicare. The $948.8 million judgment is settling for $440 million.
Omnicare filed for bankruptcy two months after the judgment. The government now stands to collect less than half, and CVS admits nothing.
- PBM Rebates
Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.
Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.
- Antitrust
Caremark wins partial dismissal while Rxeed interference claim survives
A New York federal judge dismissed Rxeed's antitrust and contractual-interference claims against Caremark. A claim concerning prospective business relationships remains pending.
- Drug Pricing
Fruth reimbursement claims move to arbitration and Missouri federal court
A West Virginia federal judge ordered arbitration of Fruth's claims against OptumRx and Caremark. Claims against Express Scripts were severed and transferred to Missouri.
- PBM Rebates
Caremark's "$8.5 billion" settlement is a projection. CVS pays nothing.
The FTC closed its insulin case against CVS's pharmacy benefit manager with conduct terms the company says it largely follows already.
- False Claims Act
CVS admitted over-dispensing insulin for a decade. The price was $37.76 million.
The admission is rare. The penalty, spread over ten years of conduct across the country's largest pharmacy chain, is small.
- Opioid Litigation
Kentucky's opioid case against two PBMs is going to federal court. Its allegations are still unanswered.
A Sixth Circuit ruling settles where the case is heard. Two years after Kentucky sued, no court has tested what Express Scripts and Optum actually did.
- FTC Enforcement
FTC pauses OptumRx insulin case to weigh proposed consent agreement
The Federal Trade Commission withdrew its insulin pricing case against UnitedHealth's OptumRx and its affiliate Emisar from adjudication to consider a proposed consent agreement. The agreement has been approved by the directors of the FTC's competition and consumer protection bureaus but still requires Commission approval, and its terms have not been disclosed.
- Controlled Substances Act
The Justice Department says CVS filled unlawful opioid prescriptions for over a decade. Nearly two years on, nothing is decided.
The complaint is an allegation, and CVS denies it. It describes a company whose own pharmacists and data raised the alarm.
- PBM Rebates
Missouri sues 19 PBMs and insulin makers over alleged pricing scheme
Missouri Attorney General Catherine Hanaway has sued 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to inflate insulin prices in violation of the Missouri Merchandising Practices Act. The state seeks injunctive relief, restitution, damages and disgorgement.
- Drug Pricing
Oregon seeks $900 million from insulin makers and PBMs over pricing
Oregon Attorney General Dan Rayfield has filed a $900 million lawsuit against Novo Nordisk, Sanofi, Eli Lilly, Express Scripts, CVS Caremark and Optum, alleging a coordinated scheme to inflate insulin and diabetes drug prices. The 173-page complaint was filed in Multnomah County Circuit Court.
- PBM Rebates
CVS Caremark becomes second major PBM to settle FTC insulin rebating case
The FTC reached a proposed consent order with CVS Health's Caremark Rx and its group purchasing organisation Zinc Health Services, resolving allegations that rebate practices inflated insulin list prices. The FTC says the terms will deliver $8.5 billion in consumer savings over a decade, plus up to $4.5 billion through point-of-sale rebates.
- FTC Enforcement
FTC settles insulin rebate case with Cigna's Express Scripts under sweeping consent order
The Federal Trade Commission settled its insulin rebating case against Express Scripts, the Cigna-owned pharmacy benefit manager. The consent order requires formulary, compensation and transparency changes that the FTC estimates will save patients up to $7 billion in out-of-pocket costs over ten years.
- FTC Report
FTC interim report finds three PBMs control nearly 80% of US prescriptions amid rebate scrutiny
The FTC's first interim staff report on pharmacy benefit managers found that the three largest PBMs processed nearly 80% of the 6.6 billion prescriptions dispensed in the US in 2023. The report documented vertical integration with insurers and specialty pharmacies and found PBM-affiliated pharmacies charging substantially higher prices than independents for the same drugs.
